|
May 22
|
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
|
|
May 22
|
European Equities Close Lower in Thursday Trading; Eurozone Business Activity Swings to Contraction
|
|
May 22
|
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
|
|
May 22
|
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
|
|
May 22
|
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
|
|
May 22
|
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
|
|
May 22
|
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
|
|
May 22
|
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
|
|
May 22
|
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
|
|
May 22
|
Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play
|
|
May 21
|
Sanofi to Buy Vigil Neuroscience for About $470 Million
|
|
May 21
|
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
|
|
May 21
|
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
|
|
May 21
|
Viz.ai, Sanofi and Regeneron to link for COPD management
|
|
May 20
|
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management
|
|
May 20
|
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
|
|
May 19
|
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
|
|
Apr 21
|
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
|
|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|